BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Akela Pharma Inc. Reports Financial Results for the Year Ended 2011


4/2/2012 11:13:13 AM

AUSTIN, TX, March 31, 2012 /PRNewswire/ - Akela Pharma, Inc. ("Akela"), (TSX: AKL), an industry leader in providing pharmaceutical contract dosage development and clinical and FDA commercial manufacturing, today announced its financial results for year ended December 31, 2011.

Total consolidated revenues for the year ended December 31, 2011 were $26.2 million, including $10.3 million in contract services, as compared to $13.3 million, including $10.2 million in contract services, for 2010.

Consolidated net income for the twelve months ended December 31, 2011 was $13.9 million or $0.43 per share, versus $1.4 million or $.05 per share, for the same respective period in 2010.

Excluding one-time items, Akela's consolidated net loss for the twelve months ended December 31, 2011 was ($0.5) million, versus a $2.1 million profit for the same period in 2010.

The Company had a cash balance of $0.1 million as of December 31, 2011 compared with $0.5 million as of December 31, 2010.

Further to the March 14, 2012 press release of Akela's CEO transition, Gregory McKee has resigned his position as member of the Board of Directors of Akela Pharma, Inc.

About Akela Pharma Inc.

Through PharmaForm, Akela's wholly owned subsidiary is a leading specialty contract service provider in the area of pharmaceutical dosage form development, preclinical, GMP clinical and FDA commercial manufacturing, specializing in controlled release and bioavailability enhancement technologies, such as hot melt extrusion, spray drying, and liquid filled capsules. Through its diverse offerings, PharmaForm solutions help pharmaceutical and biotechnology clients reach their development targets, reduce development costs and accelerate time-to-market.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES